@article{1f6dc1932b4f4f18a8aa1204e3954a16,
title = "Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial",
abstract = "We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n = 1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. Blood and Marrow Transplant Clinical Trials Network 0903/AIDS Malignancy Consortium 080 was registered at www.clinicaltrials.gov (no. NCT01410344).",
keywords = "Allogeneic hematopoietic transplantation, Bone marrow, HIV",
author = "Ambinder, {Richard F.} and Juan Wu and Brent Logan and Durand, {Christine M.} and Ryan Shields and Popat, {Uday R.} and Little, {Richard F.} and McMahon, {Deborah K.} and Joshua Cyktor and Mellors, {John W.} and Ernesto Ayala and Kaplan, {Lawrence D.} and Ariela Noy and Jones, {Richard J.} and Alan Howard and Forman, {Stephen J.} and David Porter and Carlos Arce-Lara and Paul Shaughnessy and Lisa Sproat and Hashmi, {Shahrukh K.} and Mendizabal, {Adam M.} and Horowitz, {Mary M.} and Navarro, {Willis H.} and Alvarnas, {Joseph C.}",
note = "Funding Information: Financial disclosure: Funding for this study was provided to the BMT CTN from the National Cancer Institute (NCI; no. HHSN261200622012C-009 ) and by the AMC through NCI grant U01CA121947 . The BMT CTN infrastructure is supported in part by grant U10HL069294 from the National Heart, Lung, and Blood Institute and NCI . Part of the study regarding HIV reservoir was also funded by the NCI ( K23CA177321-01A1 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: The authors thank the members of the BMT CTN, the AIDS Malignancy Consortium, research nurses, and patients who participated in this trial. The authors also thank Samantha Wilkins for help with data management and Ellen Parker for abstract and manuscript submission. Financial disclosure: Funding for this study was provided to the BMT CTN from the National Cancer Institute (NCI; no. HHSN261200622012C-009) and by the AMC through NCI grant U01CA121947. The BMT CTN infrastructure is supported in part by grant U10HL069294 from the National Heart, Lung, and Blood Institute and NCI. Part of the study regarding HIV reservoir was also funded by the NCI (K23CA177321-01A1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflict of interest statement: There are no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 2165. Publisher Copyright: {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy",
year = "2019",
month = nov,
doi = "10.1016/j.bbmt.2019.06.033",
language = "English (US)",
volume = "25",
pages = "2160--2166",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",
}